Explore the vast range of titles available.

Ischemic heart disease (IHD) has a significant impact on public health and healthcare expenditures in the United States (US). We used data from the CDC WONDER database from 1999-2020 to identify trends in the IHD-related mortality of patients ≥ 75 years in the US. AAMRs per 100,000 population and APC were calculated and categorized by year, sex, race, and geographic divisions. Between 1999 and 2020, a total of 8,124,568 IHD-related deaths were recorded. Notable declines in AAMR were observed from 1999 to 2014 (APC: -3.86) and from 2014 to 2018 (APC: -2.55), with an overall increase from 2018 to 2020 (APC: 3.76). Older men consistently demonstrated higher AAMRs than older females, with AAMRs for both sexes decreasing steadily from 1999 to 2018 and increasing in 2020. When stratified by race/ethnicity, Whites (1931.7) had the highest AAMR, followed by Blacks (1836.5), American Indians (1510.5), Hispanics (1464.4), and Asians (1093.6). Furthermore, nonmetropolitan areas (2015.2) showed greater AAMRs than metropolitan areas (1841.8). The ≥ 85-year group consistently exhibited higher IHD-related mortality rates compared to the 75-84 years group. In comparison, the older group [≥75 years] (1873.0) consistently exhibited higher IHD-related AAMRs than the younger group [<75 years] (64.0) throughout the study, showing a significant disparity. Chronic IHD (1552.0) consistently showed the highest AAMRs throughout the study, surpassing myocardial infarction (515.6), other ischemic heart diseases (24.0), and angina pectoris (5.6). Targeted interventions and resource allocation are crucial for areas with high IHD-related mortality. Public health policies should address demographic and geographical disparities, with further research for effective strategies.

Background: Prosthetic valve thrombosis is a rare but serious complication of mechanical valve replacement. Traditionally, prosthetic valve thrombosis has been managed by surgical intervention; however, there is increasing data to support the use of thrombolytics. Methods: We present a case of a 74-year-old female with a history of rheumatic fever and subsequent mechanical aortic valve replacement on warfarin who presented to the emergency department with disequilibrium and chest pain. Results: She was found to have a subtherapeutic international normalized ratio and thrombosed mechanical aortic valve seen on transthoracic echocardiography, transesophageal echocardiography, and fluoroscopy. Conclusions: She was treated with a low-dose ultraslow alteplase infusion of 25 mg of alteplase administered over 25 h. Post-infusion transthoracic echocardiography immediately following infusion and four months later confirmed resolution of thrombosis.

Background: Chemotherapy-induced cardiac dysfunction (CIC) is a significant and concerning complication observed among cancer patients. Despite the demonstrated cardioprotective benefits of statins in various cardiovascular diseases, their effectiveness in mitigating CIC remains uncertain. Objective: This meta-analysis aims to comprehensively evaluate the potential cardioprotective role of statins in patients with CIC. Methods: A systematic literature search was conducted using PubMed, Embase, and Scopus databases to identify relevant articles published from inception until 10th May 2023. The outcomes were assessed using pooled odds ratio (OR) for categorical data and mean difference (MD) for continuous data, with corresponding 95% confidence intervals (95% CIs). Results: This meta-analysis comprised nine studies involving a total of 5532 patients, with 1904 in the statin group and 3628 in the non-statin group. The pooled analysis of primary outcome shows that patients who did not receive statin suffer a greater decline in the LVEF after chemotherapy compared to those who receive statin (MD, 3.55 (95% CI: 1.04–6.05), p = 0.01). Likewise, we observed a significantly higher final mean LVEF among chemotherapy patients with statin compared to the non-statin group of patients (MD, 2.08 (95% CI: 0.86–3.30), p > 0.001). Additionally, there was a lower risk of incident heart failure in the statin group compared to the non-statin group of patients (OR, 0.41 (95% CI: 0.27–0.62), p < 0.001). Lastly, the change in the mean difference for LVEDV was not statistically significant between the statin and non-statin groups (MD, 1.55 (95% CI: −5.22–8.33), p = 0.65). Conclusion: Among patients of CIC, statin use has shown cardioprotective benefits by improving left ventricular function and reducing the risk of heart failure.

Ticagrelor is an oral antiplatelet agent commonly used following percutaneous coronary intervention (PCI). There have been many reports describing bradyarrhythmias in the setting of ticagrelor use, most notably sinus pauses. This process is thought to be related to ticagrelor's inhibition of human equilibrative nucleoside transporter (hENT1), which reduces cellular uptake of adenosine. We present a case of a 58-year-old male who experienced prolonged sinus pauses 38 hours after starting ticagrelor following ST-elevation myocardial infarction with subsequent PCI and stent placement.

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks. However, their effect on arrhythmias is not well established with limited literature. Objective This study aimed to assess the efficacy of GLP‐1 RAs and the risk of cardiac arrest and arrhythmias in obese patients based on real‐world evidence. Methods The TriNetX Global Collaborative Network research database was used to identify obese patients aged ≥ 18 years from January 2020 to December 2022. Patients were categorized into two groups, one with GLP‐1 RAs and a control group without GLP‐1 RAs. After propensity score matching (PSM), relative risk (RR) was used to compare outcomes over follow‐up periods of 1 year and 3 years. Results After 1:1 PSM, the study cohort comprised 342 753 patients in both groups. The study population had a mean age of 56.35 years. PSM analysis at 1 year follow‐up showed that the GLP‐1 RAs group of patients had a significantly lower risk of cardiac arrest (RR, 0.33 (95% CI: 0.31–0.37), p < 0.01), atrial fibrillation/flutter (RR, 0.63 (95% CI: 0.60–0.66), p < 0.01), ventricular fibrillation (RR, 0.45 (95% CI: 0.38–0.53), p < 0.01), ventricular tachycardia (RR, 0.56 (95% CI: 0.52–0.60), p < 0.01), second‐degree atrioventricular (AV) block (RR, 0.72 (95% CI: 0.63–0.82), p < 0.01), and complete heart block (RR, 0.62 (95% CI: 0.55–0.70), p < 0.01) when compared with the control group. Similar trends were observed for the 3‐year follow‐up as well. Conclusion This study suggests that GLP‐1 RAs use among obese patients was associated with lower risk of arrhythmias at both 1‐year and 3‐year follow‐ups. This study suggests that GLP‐1 RAs use among obese patients was associated with a lower risk of arrhythmias at both 1‐year and 3‐year follow‐ups.

Objective We aimed to determine if omega‐3 fatty acid (FA) supplementation significantly reduces cardiovascular (CV) events in patients with established CV disease or at high CV risk. Methods We conducted a comprehensive literature search on PubMed, Embase and Cochrane CENTRAL. The results of our analyses were presented as risk ratios (RRs) with 95% confidence intervals (CIs) and pooled using a random effects model. Meta‐regression bubble plots were generated to visualise the results of the analysis, while the detailed results were tabulated. A p‐value less than‐.05 was considered significant in all cases. Results A total of 42 studies (176 253 participants) were included in our analysis. The pooled analysis demonstrates that omega‐3 FA are associated with a significant reduction in CV mortality (p =‐.02), CV disease (p =‐.03), coronary heart disease (CHD) (p =‐.007), myocardial infarction (MI) (p =‐.008), fatal MI (p =‐.0004) and revascularisation (p =‐.003), and a significant increase in atrial fibrillation (p =‐.01), and gastrointestinal (GI) adverse events (p =‐.02). Subgroup analysis demonstrated a significant improvement with EPA monotherapy compared to EPA+DHA combination therapy in the risk of CV mortality (p = 0.01), CVD events (p <‐.00001), MACE (p < .00001), CHD (p < .00001), MI (p <‐.00001), fatal MI (p =‐.004) and revascularisation (p <‐.0001). EPA monotherapy was associated with a significant increase in the risk of atrial fibrillation (p =‐.01). Regression analysis demonstrates a dose–response relationship between omega‐3 FA (EPA or EPA+DHA) and CVD events (p =‐.001), CHD (p =‐.035), revascularisation (p =‐.035) and ischemic stroke (p =‐.003). Conclusion Our study demonstrated a significant reduction in the risk of cardiovascular outcomes with omega‐3 FA administration.

Positively significant results from the phase 3 APOLLO trial have led to its approval for the treatment of variant ATTR amyloidosis with polyneuropathy, which could potentially halt or even reverse neuropathy progression while improv-ing quality of life [1]. [...]it is noteworthy that while efficacy data have been available for patisiran, no pooled meta-analysis has attempted to comprehensively assess its safety profile. [...]we sought to conduct an analysis to provide a comprehensive understanding of the safety profile of patisiran in patients with ATTR amyloidosis. Cardiac magnetic resonance imaging (CMRI) has emerged to be a better diagnostic tooi in suspected cases. Besides diagnosing left ventricular hypertrophy (LVH) phenotypes, it also serves as a crucial modality to monitor disease pro-gression and treatment response. [...]among two randomized trials, patisiran appeared to show a non-significant trend towards reduction in the risk of all-cause mortality and any adverse cardio-vascular events.

[...]another randomized trial, conducted in Australia, reported that the addition of colchicine to Standard medical therapy did not reveal any significant difference in cardiovascular outcomes in acute coronary syndrome patients compared to placebo [6]. To better answer these controversies regarding the sig-nificance of colchicine use in combating CVD, we have performed this systematic review and meta-analysis to evaluate the effect of colchicine on cardiovascular and cer-ebrovascular events among patients with established CAD. 2 Methods This meta-analysis was conducted and reported follow-ing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [7] and performed according to established methods, as described previously [8-11]. Sec-ondary outcomes included adverse cardiovascular events (ACE), MI, all-cause mortality, and cardiovascular mortality. 2.4 Data Extraction and Quality Assessment Data from the eligible studies, such as demographic, study design, comorbidity, follow-up, and outcomes between col-chicine and placebo groups, were extracted to a Microsoft Excel(r) 2019 spreadsheet by two authors (K.K. and N.D.). [...]a total of 16 studies met the eligibility criteria and were included in the meta-analysis [3, 6,15-28].

This study compares the prognostic value of risk factors for Permanent pacemaker implantation (PPI) following transcatheter aortic valve replacement (TAVR). PubMed, Embase, Scopus, and Cochrane Library databases were searched until November 2024 for studies reporting PPI incidence within 30 days post-TAVR. A random-effect model was used to pool risk ratios (RR) and standardized mean differences (SDM) for binary and continuous risk factors. Network meta-analysis estimated pooled risk differences (ΔRR) for binary predictors with male sex as the reference. Significant predictors were ranked based on their surface under the cumulative ranking curve (SUCRA) values. A total of 108 studies comprising 77,538 patients (14,560 requiring PPI) were included. Male sex (RR: 1.13), baseline atrial fibrillation (AF) (RR: 1.12), 2nd degree Mobitz I (RR: 5.16) and Mobitz II (RR: 2.30) atrioventricular blocks (AVB), 3rd degree AVB (RR: 13.46), left anterior (LAHB) (RR: 1.79) and posterior hemiblocks (LPHB) (RR: 2.57), bifascicular block (RR: 2.34), right bundle branch block (RBBB) (RR: 3.20) and intraprocedural AVB (RR: 4.15) were identified as predictors for PPI post-TAVR. The risk of PPI was higher with self-expandable valves (RR: 1.79), subclavian access (RR: 1.75), and 29 mm prostheses (RR: 1.33) compared to balloon-expandable valves, transfemoral access, and 23 mm prostheses. Network meta-analysis ranked 3rd degree AVB (SUCRA <0.01), Mobitz I AVB (SUCRA: 0.14), Mobitz II AVB (SUCRA: 0.33), intraprocedural AVB (SUCRA: 0.42), bifascicular block (SUCRA: 0.48), RBBB (SUCRA: 0.49) and LPHB (SUCRA: 0.54) as major predictors of PPI in descending order of significance. In conclusion, clinicians should closely monitor conduction abnormalities as key predictors of PPI following TAVR. Additionally, other risk factors such as subclavian access, self-expanding implantation, AF, large prosthesis diameter, and male sex should not be overlooked. [Display omitted]